Table 1.
List of the 20 most mutated genes by lung cancer subtype (adapted from [37]).
| AC | LCC | NCSLC | SCLC | ADC |
|---|---|---|---|---|
| EGFR (31%) | TP53 (68%) | EGFR (25%) | TP53 (63%) | TP53 (57%) |
| KRAS (17%) | KRAS (22%) | KRAS (16%) | RB1 (46%) | EGFR (7%) |
| TP53 (42%) | EGFR (5%) | TP53 (31%) | LRP1B (25%) | LRP1B (37%) |
| STK11 (11%) | STK11 (8%) | ARID1A (25%) | KMT2D (16%) | PIK3CA (8%) |
| BRAF (3%) | PIK3CA (4%) | PIK3CA (4%) | EGFR (6%) | NFE2L2 (12%) |
| KEAP1 (15%) | NRAS (3%) | ALK (17%) | NOTCH1 (9%) | KRAS (4%) |
| MET (3%) | MET (3%) | BRAF (2%) | PIK3CA (7%) | KMT2D (17%) |
| LRP1B (28%) | KEAP1 (21%) | MET (2%) | PTEN (6%) | CDKN2A (11%) |
| ERBB2 (2%) | AR (32%) | STK11 (7%) | EP300 (8%) | FAT4 (16%) |
| PIK3CA (4%) | BRAF (2%) | KEAP1 (16%) | FAT1 (9%) | KMT2C (15%) |
| SMARCA4 (9%) | PTEN (4%) | CDKN2A (4%) | ATRX (8%) | KEAP1 (9%) |
| NF1 (8%) | CDKN2A (5%) | ATM (13%) | KMT2C (8%) | NF1 (11%) |
| ATM (7%) | LRP1B (28%) | KMT2D (24%) | CREBBP (8%) | PTEN (7%) |
| FAT1 (8%) | POLQ (28%) | SMARCA4 (10%) | GRIN2A (8%) | ERBB4 (8%) |
| PTPRT (9%) | HRAS (4%) | NF1 (9%) | FAT4 (10%) | FAT1 (12%) |
| KMT2C (9%) | GNAS (4%) | SETBP1 (10%) | ROS1 (8%) | ROS1 (10%) |
| RBM10 (8%) | ERBB4 (5%) | FAT1 (15%) | ERBB4 (6%) | PREX2 (13%) |
| KMT2D (7%) | ATM (6%) | ERBB2 (2%) | ARID1A (6%) | PDE4DIP (11%) |
| FAT4 (16%) | FLT3 (7%) | TET2 (8%) | ZNF521 (7%) | ZFHX3 (9%) |
| ERBB4 (5%) | ZFHX3 (21%) | NOTCH1 (3%) | MTOR (5%) | GRIN2A (10%) |
Abbreviations: EGF—epidermal growth factor receptor; KRAS—Kirsten rat sarcoma virus; TP53—tumor protein p53; STK11—serine/threonine kinase 11; BRAF—B-Raf proto-oncogene, serine/threonine kinase; Keap1-Kelch-like ECH-associated protein 1; MET—MET proto-oncogene, receptor tyrosine kinase; LRP1B—LDL receptor-related protein 1B; ERBB2-Erb-B2 receptor tyrosine kinase 2; PIK3CA—phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; SMARCA4—SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4; NF1—neurofibromin 1; ATM-ATM serine/threonine kinase; FAT1—FAT atypical cadherin 1; PTPRT-protein tyrosine phosphatase receptor type T; KMT2C-lysine methyltransferase 2C; RBM10 (RNA binding motif protein 10; KMT2D—lysine methyltransferase 2D; FAT4—FAT atypical cadherin 4; ERBB4—Erb-B2 receptor tyrosine kinase 4; NRAS—NRAS proto-oncogene, GTPase; AR—androgen receptor; PTEN—phosphatase and tensin homolog; CDKN2A—cyclin-dependent kinase inhibitor 2A; POLQ—DNA polymerase theta; HRAS—HRas proto-oncogene, GTPase; GNAS—GNAS complex locus; FLT3—Fms-related receptor tyrosine kinase 3; ZFHX3—zinc finger homeobox 3; ARID1A—AT-rich interaction domain 1A; ALK—ALK receptor tyrosine kinase; SETBP1—SET binding protein 1; TET2—tet methylcytosine dioxygenase 2; Notch 1—neurogenic locus notch homolog protein 1; RB1—RB transcriptional corepressor 1; EP300 Gene—E1A binding protein P300; ATRX—ATRX chromatin remodeler; CREBBP—CREB binding protein; GRIN2A—glutamate ionotropic receptor NMDA type subunit 2A; ROS1—ROS proto-oncogene 1, receptor tyrosine kinase; ZNF521—zinc finger protein 521; MTOR—mechanistic target of rapamycin kinase; NFE2L2—NFE2-like BZIP transcription factor 2; REX2—phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2; PDE4DIP—phosphodiesterase 4D interacting protein.